Ymke van der Pol
Overview
Explore the profile of Ymke van der Pol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arafa A, Yadav S, Marshall C, Mauer E, Huang M, Yilma B, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 40019487
Background: Germline alterations in homologous recombination repair (gHRR) genes impact the pathogenesis, treatment options, and survival of cancer patients. However, distinct gHRR gene alterations may differentially impact treatment response and...
2.
Chen L, Jager M, Rebergen D, Brink G, Ende T, Vanderlinden W, et al.
Genome Res
. 2025 Jan;
PMID: 39805703
Shallow genome-wide cell-free DNA (cfDNA) sequencing holds great promise for non-invasive cancer monitoring by providing reliable copy number alteration (CNA) and fragmentomic profiles. Single nucleotide variations (SNVs) are, however, much...
3.
Ende T, Kuijper S, Widaatalla Y, Noortman W, van Velden F, Woodruff H, et al.
Int J Radiat Oncol Biol Phys
. 2024 Oct;
121(4):963-974.
PMID: 39424077
Purpose: The value of integrating clinical variables, radiomics, and tumor-derived cell-free DNA (cfDNA) for the prediction of survival and response to chemoradiation of patients with resectable esophageal adenocarcinoma is not...
4.
Moldovan N, Verkuijlen S, van der Pol Y, Bosch L, van Weering J, Bahce I, et al.
iScience
. 2024 Sep;
27(9):110742.
PMID: 39262778
Blood contains multiple analytes that can be used as liquid biopsy to analyze cancer. Mutations have been detected in DNA associated with small extracellular vesicles (sEVs). The genome-wide composition and...
5.
Wever B, Schaafsma M, Bleeker M, van den Burgt Y, van den Helder R, Lok C, et al.
Commun Med (Lond)
. 2024 May;
4(1):88.
PMID: 38755429
Background: High ovarian cancer mortality rates motivate the development of effective and patient-friendly diagnostics. Here, we explored the potential of molecular testing in patient-friendly samples for ovarian cancer detection. Methods:...
6.
Moldovan N, van der Pol Y, Ende T, Boers D, Verkuijlen S, Creemers A, et al.
Cell Rep Med
. 2023 Dec;
5(1):101349.
PMID: 38128532
The structure of cell-free DNA (cfDNA) is altered in the blood of patients with cancer. From whole-genome sequencing, we retrieve the cfDNA fragment-end composition using a new software (FrEIA [fragment...
7.
van der Pol Y, Tantyo N, Evander N, Hentschel A, Wever B, Ramaker J, et al.
EMBO Mol Med
. 2023 Nov;
15(12):e17282.
PMID: 37942753
Cell-free DNA (cfDNA) can be isolated and sequenced from blood and/or urine of cancer patients. Conventional short-read sequencing lacks deployability and speed and can be biased for short cfDNA fragments....
8.
van der Pol Y, Moldovan N, Ramaker J, Bootsma S, Lenos K, Vermeulen L, et al.
Genome Biol
. 2023 Oct;
24(1):229.
PMID: 37828498
Background: Existing methods to detect tumor signal in liquid biopsy have focused on the analysis of nuclear cell-free DNA (cfDNA). However, non-nuclear cfDNA and in particular mitochondrial DNA (mtDNA) has...
9.
Ende T, van der Pol Y, Creemers A, Moldovan N, Boers D, van Berge Henegouwen M, et al.
J Pathol
. 2023 Aug;
261(3):286-297.
PMID: 37615198
Circulating tumor DNA (ctDNA) holds promise in resectable esophageal adenocarcinoma (EAC) to predict patient outcome but is not yet sensitive enough to be clinically applicable. Our aim was to combine...
10.
van der Pol Y, Moldovan N, Verkuijlen S, Ramaker J, Boers D, Onstenk W, et al.
Clin Chem
. 2022 Mar;
68(6):803-813.
PMID: 35292813
Background: Assays that account for the biological properties and fragmentation of cell-free DNA (cfDNA) can improve the performance of liquid biopsy. However, preanalytic and physiological differences between individuals on fragmentomic...